ISPOR Europe 2022 Home
  • About
    • News Center
  • Award Winners
  • Program
    • Program
      • Session
      • Paper
    • Learning Formats
    • Plenary Sessions
    • Spotlight Sessions
    • Posters
    • Educational Symposia & HEOR Theater
    • Program Committee
    • Speaker & Poster Presenter Resources
    • Student Program
  • Exhibits & Sponsorship
    • Sponsor List
    • Exhibitor List
    • Media Partners
  • Photo Gallery
large-circle

ISPOR Europe 2022

6 - 9 November

  • Home
  • Events
  • Past Conferences
  • ISPOR Europe 2022
  • Program
  • Program
  • Session

  • Long-Term Health and Economic Benefits of Switching to Tenofovir Alafenamide Versus Continuing on Entecavir in Chronic Hepatitis B Patients with Low-Level Viremia in Saudi Arabia

    Nov 9, 2022, 09:00 AM
  • «
  • 431
  • 432
  • 433
  • 434
  • 435
  • 436
  • 437
  • 438
  • 439
  • 440 (current)
  • »
Quick Links
  • About
  • Media Center
  • Exhibits & Sponsorships
  • Contact Us
Policies & Legal
  • Antitrust Compliance
  • Code of Ethics
  • Cookie Policy
  • Diversity Policy
  • Funding Statement
  • Legal Disclaimer
  • Privacy Policy
  • Terms and Conditions

Subscribe

Join ISPOR

ISPOR–The Professional Society for
Health Economics and Outcomes Research

Copyright © 2018 ISPOR. All rights reserved.

International Society for Pharmacoeconomics and Outcomes Research, Inc

Website Design & Development by Matrix Group